Medicine Man Company Insiders

SHWZ Stock  USD 0.01  0.01  72.50%   
Medicine Man employs about 389 people. The company is managed by 10 executives with a total tenure of roughly 908 years, averaging almost 90.0 years of service per executive, having 38.9 employees per reported executive. Break down of Medicine Man's management performance can provide insight into the company performance.
Daniel Pabon  Insider
Chief Counsel
Jim Parco  Insider
Pres Ltd
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Medicine Man Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.

Medicine Man Management Team Effectiveness

The company has return on total asset (ROA) of 0.0452 % which means that it generated a profit of $0.0452 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1569 %, meaning that it created $0.1569 on every $100 dollars invested by stockholders. Medicine Man's management efficiency ratios could be used to measure how well Medicine Man manages its routine affairs as well as how well it operates its assets and liabilities.

Medicine Man Workforce Comparison

Medicine Man Technologies is rated fifth in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is at this time estimated at about 10,028. Medicine Man holds roughly 389 in number of employees claiming about 4% of equities under Drug Manufacturers—Specialty & Generic industry.
The company has Profit Margin (PM) of 0.15 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.13 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.13.

Medicine Man Technologies Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Medicine Man Technologies Price Series Summation is a cross summation of Medicine Man price series and its benchmark/peer.

Medicine Man Notable Stakeholders

A Medicine Man stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Medicine Man often face trade-offs trying to please all of them. Medicine Man's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Medicine Man's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.

About Medicine Man Management Performance

The success or failure of an entity such as Medicine Man Technologies often depends on how effective the management is. Medicine Man management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Medicine management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Medicine management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Medicine Man Technologies, Inc., doing business as Schwazze, operates as a cannabis company. The company was incorporated in 2014 and is headquartered in Denver, Colorado. Medicine Man operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 389 people.
Please note, the imprecision that can be found in Medicine Man's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Medicine Man Technologies. Check Medicine Man's Beneish M Score to see the likelihood of Medicine Man's management manipulating its earnings.

Medicine Man Workforce Analysis

Traditionally, organizations such as Medicine Man use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Medicine Man within its industry.

Medicine Man Manpower Efficiency

Return on Medicine Man Manpower

Revenue Per Employee278.7K
Revenue Per Executive10.8M
Net Income Per Employee37.3K
Net Income Per Executive1.5M

Additional Tools for Medicine Pink Sheet Analysis

When running Medicine Man's price analysis, check to measure Medicine Man's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medicine Man is operating at the current time. Most of Medicine Man's value examination focuses on studying past and present price action to predict the probability of Medicine Man's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medicine Man's price. Additionally, you may evaluate how the addition of Medicine Man to your portfolios can decrease your overall portfolio volatility.